PSC In The News
Geronimus discusses causes, potential solutions to racial disparities in infant mortality
Highlights
Arline Geronimus wins Excellence in Research Award from School of Public Health
Yu Xie to give DBASSE's David Lecture April 30, 2013 on "Is American Science in Decline?"
U-M grad programs do well in latest USN&WR "Best" rankings
Sheldon Danziger named president of Russell Sage Foundation
Back in September
Follow us Approval Times for New Drugs: Does the Funding Source for FDA Staff Matter?
Carpenter, D., Michael Chernew, D.G. Smith, and A. Mark Fendrick. 2003. "Approval Times for New Drugs: Does the Funding Source for FDA Staff Matter?" Health Affairs. Web-Exclusive Supplement W3, 618-624.
The Food and Drug Administration (FDA) has been criticized for injudicious and excessively rapid approval of new drugs as a result of pharmaceutical industry influence. Many critics focus on the Prescription Drug User Fee Act (PDUFA) of 1992, which augmented the FDA's budget through the charging of user fees. We assess the effect of FDA staffing patterns and attributes of submitting firms on approval times for 843 new drug applications (NDAs) submitted between 1977 and 2000. NDA review times shortened by 3.3 months for every 100 additional FDA staff. The amount of funding for FDA staff appears to be a much more important influence on NDA review time than the source of funding.
Browse | Search : All Pubs | Next